249P A phase I/II study of RC148 (PD-1/VEGF bispecific antibody) monotherapy or in combination with docetaxel for the treatment of first- or second-line locally advanced or metastatic non-small cell lung cancer (la/mNSCLC) without actionable genomic alterations (AGA)
Year: 2025
Type: article
Study design: Clinical Trial
Abstract: RC148 is an innovative bispecific antibody targeting both PD-1 and vascular endothelial growth factor (VEGF). Dual targeting of PD-1 and VEGF combines two complementary modalities, aiming to improve anti-tumor effects by inhibiting PD-1-mediated immunosuppression and blocking tumor angiogenesis in the tumor microenvironment. This study aimed to evaluate the efficacy and safety of RC148 monotherapy and in combination with docetacel in patients (pts) with la/m NSCLC.
Source: Immuno-Oncology Technology
Institutions: Shandong Tumor Hospital, Jinan Central Hospital, Shandong First Medical University, Guilin Medical University, Zhejiang Cancer Hospital, Shanxi Provincial Cancer Hospital, Fujian Provincial Cancer Hospital, Harbin Medical University, Sheng Jing Hospital, China Medical University, Capital Medical University, Beijing Tian Tan Hospital, First Affiliated Hospital of Zhengzhou University, Sichuan Cancer Hospital, Hunan Cancer Hospital, Peking University Cancer Hospital, Tongji University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,340
OpenAlex ID: W7117304398
FWCI:
Cites:
Cited by:
Related to: